glp 1 heart failure reduced ejection fraction SGLTi and GLP-1 in HF Effects of GLP-1 Receptor Agonists

Key Takeaways Foundayo (orforglipron) is the first oral GLP-1 receptor agonist that can be taken any time of day without food or water restrictions FDA approved April 1, 2026 for chronic weight management Average weight loss in the ATTAIN-1 trial was 11.2% at 72 weeks at the highest dose less than injectable Wegovy (14.9%) or Zepbound (20.2%) Its small-molecule structure allows consistent absorption regardless of what is in the stomach Side effect profile is similar to other GLP-1 medications primarily gastrointestinal Starting cost is approximately $25/month with commercial insurance + Lilly savings card, $149/month self-pay for the lowest dose Best suited for patients with needle aversion, complicated schedules, or those who struggled with oral Wegovys fasting requirements Not recommended for patients already responding well to injectable GLP-1s Cannot be combined with other GLP-1 medications References Eli Lilly and Company

doi:10.5173/ceju.2022.129 8

Yes, and research shows semaglutide does not significantly affect oral contraceptive absorption

Vitamin C & Acerola Cherry Extract: Help support collagen formation and antioxidant protection

31 Right upper quadrant abdominal rigidity R19.32 Left upper quadrant abdominal rigidity R19.33 Right lower quadrant abdominal rigidity R19.34 Left lower quadrant abdominal rigidity R19.35 Periumbilic abdominal rigidity R19.36 Epigastric abdominal rigidity R19.37 Generalized abdominal rigidity R19.4 Change in bowel habit Excludes1: constipation (K59.0-) functional diarrhea (K59.1) R19.5 Other fecal abnormalities Abnormal stool color Bulky stools Mucus in stools Occult blood in feces Occult blood in stools Excludes1: melena (K92.1) neonatal melena (P54.1) R19.6 Halitosis R19.7 Diarrhea, unspecified Diarrhea NOS Excludes1: functional diarrhea (K59.1) neonatal diarrhea (P78.3) psychogenic diarrhea (F45.8) R19.8 Other specified symptoms and signs involving the digestive system and abdomen Symptoms and signs involving the skin and subcutaneous tissue (R20-R23) Excludes2: symptoms relating to breast (N64.4-N64.5) R20 Disturbances of skin sensation Excludes1: dissociative anesthesia and sensory loss (F44.6) psychogenic disturbances (F45.8) R20.0 Anesthesia of skin R20.1 Hypoesthesia of skin R20.2 Paresthesia of skin Formication Pins and needles Tingling skin Excludes1: acroparesthesia (I73.8) R20.3 Hyperesthesia R20.8 Other disturbances of skin sensation R20.9 Unspecified disturbances of skin sensation ==R21